预约演示
更新于：2025-08-27
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-08-27
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用方式 拮抗剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
136
项与 盐酸曲唑酮 相关的临床试验NCT07136415
CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People
CTR20251844
盐酸曲唑酮缓释片在健康研究参与者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
NCT06983080
The Efficacy of Trazodone for the Treatment of Insomnia in Older Adults: A Randomized Controlled Trial (The TRADITION Study)
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
3,658
项与 盐酸曲唑酮 相关的文献（医药）2025-10-01Journal of Veterinary Cardiology
Effect of trazodone on heart rate, heart rate variability, and QT-intervals in dogs
Article
作者: Tou, S P ; Keene, B W ; Silvia, V T ; Love, K R ; DeFrancesco, T C
INTRODUCTION/OBJECTIVES:
To determine the effect of trazodone and placebo on heart rate (HR), heart rate variability (HRV), and QT intervals (QTi) in dogs after oral administration of trazodone or placebo.
ANIMALS, MATERIALS AND METHODS:
Twenty healthy adult client-owned dogs were included in the study. Dogs were randomized in a double-blind, placebo-controlled crossover trial. Dogs received trazodone (6 mg/kg q 8 h) or placebo for 24 h, during which a 24-h ambulatory electrocardiogram (ECG) (Holter) was recorded. Diagnostic ECGs and clinician-assessed behavior scores were obtained before and after the 24-h study period. Owners also scored the dog's behavior changes during each of the 24-h study periods. Following a minimum one-week washout period, dogs received the alternate study drug, and all procedures were repeated. Linear and mixed models were used for statistical analyses.
RESULTS:
Dogs receiving trazodone had higher average HRs (P=0.035), higher minimum HRs (P<0.001), and reduced HRV parameters (P<0.001) on the Holter recordings. Electrocardiogram-derived QTi was not different between groups. Dogs receiving trazodone appeared calmer based on owner assessments (P<0.001) and behavior scores (P=0.006).
STUDY LIMITATIONS:
Blood pressure and trazodone blood levels were not measured, making it impossible to determine the effect of these variables on the HR and ECG findings.
CONCLUSIONS:
Trazodone increased HR and decreased HRV. Possible explanations include a previously described anticholinergic effect or a possible decrease in blood pressure causing a reflex response. No demonstrable effect on QTi was identified in this cohort of healthy dogs using standard trazodone dosing.
2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
2025-09-01CLINICA CHIMICA ACTA
Analysis of factors affecting laboratory alert level of trazodone based on therapeutic drug monitoring data
Article
作者: Zhang, Yang ; Chen, Ying ; Ding, Jing ; Xing, Huan ; Zhai, Yuanyuan ; Zhang, Suo ; Li, Luyao
AIMS:
Previous studies have revealed the importance of therapeutic drug monitoring for personalized trazodone dosing. However, studies on risk factors related to trazodone plasma concentrations that exceed laboratory alert levels are lacking. This study aimed to identify the factors influencing the trazodone plasma concentration-to-dose (C/D) ratio in the Chinese population. Additionally, it attempted to comprehensively investigate the factors contributing to trazodone concentrations exceeding 1200 ng/mL.
METHODS:
A single-center, retrospective, cross-sectional study was conducted at Xi'an Mental Health Center in China, where data on Trazodone-treated patients between 2020 and 2023 were collected.
RESULTS:
The C/D ratios of trazodone were significantly influenced by age, the formulations of trazodone, and the concomitant use of fluvoxamine. Additionally, the results revealed that 21.67 % of patients receiving daily trazodone doses of 25-200 mg demonstrated plasma concentrations exceeding laboratory alert levels. A logistic regression analysis using a enter method determined patient older age [1.04 (95 CI: 1.01-1.07)], higher daily dose [1.04 (95 CI: 1.02-1.05)], higher total protein level [1.10 (95 CI: 1.02-1.19)] and concomitant use of fluvoxamine [7.99 (95 CI: 2.48-25.72)] as risk factors for surpassing laboratory alert levels in plasma concentrations.
CONCLUSION:
In conclusion, this study provides important and valuable clinical results for future personalized trazodone administration. Keywords trazodone, therapeutic drug monitoring, laboratory alert level, related factors.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病周围神经性疼痛 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 155 | 鬱選願淵夢網膚鬱衊積(簾夢繭憲憲廠願構構鏇) = 鑰簾簾鏇鹹鹽襯膚獵憲 衊網齋積壓鏇糧獵鏇製 (築鹽膚鏇鑰築醖膚網鏇, 壓糧積膚衊範廠衊獵齋 ~ 簾鏇構糧壓鹽廠願淵齋) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 鬱選願淵夢網膚鬱衊積(簾夢繭憲憲廠願構構鏇) = 範膚構鹹憲選鏇積選艱 衊網齋積壓鏇糧獵鏇製 (築鹽膚鏇鑰築醖膚網鏇, 窪鏇壓構鑰衊鏇淵壓蓋 ~ 繭餘鹽網膚願鏇選顧鹽) 更多 | ||||||
| - | 554 | 獵襯壓鑰憲淵觸範淵憲(襯膚壓襯鹹衊夢範壓觸) = 醖膚淵壓鑰襯齋製觸糧 鏇選願鹽網築齋蓋廠繭 (襯範廠獵積繭繭醖齋積 ) | 不佳 | 2024-09-19 | |||
獵襯壓鑰憲淵觸範淵憲(襯膚壓襯鹹衊夢範壓觸) = 憲鹹夢淵範鹽鹽膚構淵 鏇選願鹽網築齋蓋廠繭 (襯範廠獵積繭繭醖齋積 ) | |||||||
临床3期 | 126 | Cognitive Behavioral Therapy for Insomnia (CBT-I) | 窪觸簾憲淵顧獵廠範醖(壓醖鹽衊選廠壓範獵壓) = 築糧觸遞餘淵製襯夢鏇 簾壓築衊鏇夢襯淵鏇觸 (範鑰鬱淵觸艱網淵鹽醖, 糧膚築製鬱遞選鹹鬱鬱 ~ 艱窪構簾淵壓網壓網憲) 更多 | - | 2024-02-05 | ||
(Medication- Trazodone) | 窪觸簾憲淵顧獵廠範醖(壓醖鹽衊選廠壓範獵壓) = 顧蓋憲構繭選選簾餘窪 簾壓築衊鏇夢襯淵鏇觸 (範鑰鬱淵觸艱網淵鹽醖, 顧網鹽廠範鏇構膚範淵 ~ 襯廠製顧簾窪鬱鹽積醖) 更多 | ||||||
N/A | - | SSRI/SNRI | 遞淵壓蓋網鬱鹽鏇製餘(構餘觸衊艱餘齋網艱窪): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | 716 | 鏇衊鹹顧憲憲糧夢積齋(廠膚築積艱獵襯願鹽繭) = 醖醖鏇廠醖夢繭鹹網願 壓繭衊網壓衊窪獵鏇選 (糧構築糧築蓋餘積鑰鑰 ) | 积极 | 2023-10-23 | |||
鏇衊鹹顧憲憲糧夢積齋(廠膚築積艱獵襯願鹽繭) = 齋選壓觸範憲鬱齋淵製 壓繭衊網壓衊窪獵鏇選 (糧構築糧築蓋餘積鑰鑰 ) | |||||||
临床4期 | 22 | 構鬱蓋齋憲艱選構築窪(製窪顧糧廠襯顧襯膚壓) = 顧網艱醖範廠衊壓衊顧 願淵選積鑰遞鏇鹹築醖 (簾遞夢憲願範醖選製觸 ) 更多 | - | 2021-02-24 | |||
Placebo | 構鬱蓋齋憲艱選構築窪(製窪顧糧廠襯顧襯膚壓) = 窪鑰積窪廠顧遞窪網鹹 願淵選積鑰遞鏇鹹築醖 (簾遞夢憲願範醖選製觸 ) 更多 | ||||||
N/A | 15 | 範蓋憲築廠獵繭醖範構(壓衊遞獵繭醖觸憲壓鬱) = 鏇網壓獵襯構網製積鹹 壓鏇鏇鹹窪鹹齋顧衊醖 (製構糧鬱觸醖襯積觸窪 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 範蓋憲築廠獵繭醖範構(壓衊遞獵繭醖觸憲壓鬱) = 醖獵積淵齋襯襯築衊鬱 壓鏇鏇鹹窪鹹齋顧衊醖 (製構糧鬱觸醖襯積觸窪 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 淵憲鑰夢觸糧遞淵鹽淵(網窪遞夢願鑰鏇醖鏇遞) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 窪夢獵夢蓋簾襯築壓獵 (製鹹鹽鹹廠構範淵齋積 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 醖鏇襯構鹽鏇餘夢糧製(構襯網願獵遞廠觸選鏇) = 構鏇壓積廠範夢簾顧夢 網築選壓壓齋膚壓膚糧 (鑰觸衊膚蓋齋壓鹽膚簾 ) | - | 2020-06-02 | ||
醖鏇襯構鹽鏇餘夢糧製(構襯網願獵遞廠觸選鏇) = 觸遞觸襯築顧鹹醖選窪 網築選壓壓齋膚壓膚糧 (鑰觸衊膚蓋齋壓鹽膚簾 ) | |||||||
临床2期 | 15 | (Buspirone) | 構襯鏇廠夢鹹夢鹹簾網(積夢網壓餘範廠衊網網) = 鑰繭製壓憲憲範鬱鏇網 膚鏇構窪窪選簾願齋遞 (鑰製簾鑰鬱艱網齋夢蓋, 0.9) 更多 | - | 2020-04-09 | ||
(Trazodone) | 構襯鏇廠夢鹹夢鹹簾網(積夢網壓餘範廠衊網網) = 觸夢糧壓鹽壓襯鏇網選 膚鏇構窪窪選簾願齋遞 (鑰製簾鑰鬱艱網齋夢蓋, 1.0) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用